Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KIT positive |
Therapy | Imatinib + Letrozole |
Indication/Tumor Type | breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT positive | breast cancer | predicted - sensitive | Imatinib + Letrozole | Phase 0 | Actionable | In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884). | 18248884 |
PubMed Id | Reference Title | Details |
---|---|---|
(18248884) | Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. | Full reference... |